Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback